Palivizumab-resistant human respiratory syncytial virus infection in infancy

scientific article published in July 2010

Palivizumab-resistant human respiratory syncytial virus infection in infancy is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1086/653534
P698PubMed publication ID20528472
P5875ResearchGate publication ID44654309

P50authorErtan MayatepekQ88240251
P2093author name stringMarkus Vogel
Thomas Hoehn
Ortwin Adams
Alexander Kovacevic
Linda Bonzel
P433issue2
P407language of work or nameEnglishQ1860
P921main subjectrespiratory syncytial virusQ1052913
P304page(s)185-188
P577publication date2010-07-01
P1433published inClinical Infectious DiseasesQ5133764
P1476titlePalivizumab-resistant human respiratory syncytial virus infection in infancy
P478volume51

Reverse relations

cites work (P2860)
Q34542805A cell based high-throughput screening approach for the discovery of new inhibitors of respiratory syncytial virus
Q54232019Complete Genome Sequence of an ON1 Human Respiratory Syncytial Virus Strain Isolated in Lebanon in 2015.
Q42275949Cross-neutralization of four paramyxoviruses by a human monoclonal antibody
Q92360246Crystal Structure and Immunogenicity of the DS-Cav1-Stabilized Fusion Glycoprotein From Respiratory Syncytial Virus Subtype B
Q64121419Detection of ON1 and novel genotypes of human respiratory syncytial virus and emergence of palivizumab resistance in Lebanon
Q42251545Detection of respiratory syncytial virus fusion protein variants between 2009 and 2012 in China
Q64054630Emergence of new antigenic epitopes in the glycoproteins of human respiratory syncytial virus collected from a US surveillance study, 2015–17
Q37732535Escape from neutralization by the respiratory syncytial virus-specific neutralizing monoclonal antibody palivizumab is driven by changes in on-rate of binding to the fusion protein
Q30375062GS-5806 Inhibits a Broad Range of Respiratory Syncytial Virus Clinical Isolates by Blocking the Virus-Cell Fusion Process
Q39460933Genetic variability of subgroup A and B respiratory syncytial virus strains circulating in southwestern China from 2009 to 2011.
Q30148692Global epidemiology of non-influenza RNA respiratory viruses: data gaps and a growing need for surveillance
Q28483402High throughput screening for small molecule enhancers of the interferon signaling pathway to drive next-generation antiviral drug discovery
Q28245563Identification of nucleolin as a cellular receptor for human respiratory syncytial virus
Q37997822Identifying targets in the hunt for effective respiratory syncytial virus interventions
Q38387416Molecular characterization of respiratory syncytial viruses infecting children reported to have received palivizumab immunoprophylaxis
Q35845854Molecular evolution of respiratory syncytial virus fusion gene, Canada, 2006-2010.
Q33860620NEP: web server for epitope prediction based on antibody neutralization of viral strains with diverse sequences
Q40059727Neutralizing epitopes of RSV and palivizumab resistance in Japan
Q30413158Passive immune neutralization strategies for prevention and control of influenza A infections
Q28287657RSV fusion: time for a new model
Q37123109Residue-level prediction of HIV-1 antibody epitopes based on neutralization of diverse viral strains
Q45325102Respiratory Syncytial Virus (RSV): Targeting the G Protein Provides a New Approach for an Old Problem.
Q58595178Respiratory syncytial virus fusion nanoparticle vaccine immune responses target multiple neutralizing epitopes that contribute to protection against wild-type and palivizumab-resistant mutant virus challenge
Q39719279Respiratory syncytial virus prevention in children with congenital heart disease: who and how?
Q45359023Selection and characterization of human respiratory syncytial virus escape mutants resistant to a polyclonal antiserum raised against the F protein
Q28272863The RSV fusion receptor: not what everyone expected it to be
Q55447639The human viral challenge model: accelerating the evaluation of respiratory antivirals, vaccines and novel diagnostics.
Q47549703Verdinexor Targeting of CRM1 is a Promising Therapeutic Approach against RSV and Influenza Viruses

Search more.